Skip to content
2000
image of Subtle Intrusion: Minimal Serous Uterine Carcinoma in an Asymptomatic Postmenopausal Patient-A Case Report

Abstract

Introduction

Minimal serous uterine cancers (MUSCs) represent a distinct subset of endometrial malignancies characterized by early-stage presentation and unique histopathological features. These tumors typically manifest as intraepithelial or superficial serous carcinomas confined to endometrial polyps without myometrial invasion or lymphovascular involvement. MUSCs are predominantly diagnosed in postmenopausal women and are associated with favorable prognosis.

Case Presentation

The present case report briefs the finding of a 60-year-old woman presenting to the gynecological outpatient department for a routine gynaecological check-up. She was a known case of type II diabetes mellitus, hypertension, and asthma. She had no history of postmenopausal bleeding or vaginal discharge. Incidentally, on per speculum examination, a polyp of 2x3 cm was seen protruding through the cervical opening (cervical os). Her transvaginal ultrasound revealed a postmenopausal uterus with a thickened endometrium of 10mm. Her histopathology report of dilatation and curettage with polypectomy revealed serous carcinoma against the background of atrophic endometrium. The patient was managed with staging laparotomy with Wertheim’s hysterectomy with bilateral pelvic lymph node dissection, omentectomy, and parietal peritoneum biopsy. Her final histopathology report revealed Stage 1A MUSC with atrophic endometrium.

Conclusion

The case report highlights the clinical significance of recognizing MUSC as an early-stage variant of endometrial cancer. Postmenopausal women, vulnerable to uterine serous carcinoma, require comprehensive sampling of all endometrial biopsies, curettings, and endometrial polyps to ensure early detection and accurate staging.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cas/10.2174/0118746098347939250407050519
2025-04-23
2025-10-03

  • From This Site

    /content/journals/cas/10.2174/0118746098347939250407050519
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Cancer trends - endometrial cancer statistics. 2022 https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/#:~:text=Latest%20endometrial%20cancer%20data,ASR%20%3D%20age-standardised%20rates
  2. Maheshwari A. Kumar N. Mahantshetty U. Gynecological cancers: A summary of published Indian data. South Asian J. Cancer 2016 5 3 112 120 10.4103/2278‑330X.187575 27606294
    [Google Scholar]
  3. Baker-Rand H. Kitson S.J. Recent advances in endometrial cancer prevention, early diagnosis and treatment. Cancers 2024 16 5 1028 10.3390/cancers16051028 38473385
    [Google Scholar]
  4. Idrees R. Din N.U. Fatima S. Kayani N. Serous carcinoma arising in endometrial polyps: Clinicopathologic study of 4 cases. Ann. Diagn. Pathol. 2013 17 3 256 258 10.1016/j.anndiagpath.2012.11.003 23276456
    [Google Scholar]
  5. Ferriss J.S. Erickson B.K. Shih I.M. Fader A.N. Uterine serous carcinoma: Key advances and novel treatment approaches. Int. J. Gynecol. Cancer 2021 31 8 1165 1174 10.1136/ijgc‑2021‑002753 34210768
    [Google Scholar]
  6. Bogani G. Ray-Coquard I. Concin N. Ngoi N.Y.L. Morice P. Enomoto T. Takehara K. Denys H. Nout R.A. Lorusso D. Vaughan M.M. Bini M. Takano M. Provencher D. Indini A. Sagae S. Wimberger P. Póka R. Segev Y. Kim S.I. Candido dos Reis F.J. Lopez S. Mariani A. Leitao M.M. Jr Raspagliesi F. Panici P.B. Donato D.V. Muzii L. Colombo N. Scambia G. Pignata S. Monk B.J. Uterine serous carcinoma. Gynecol. Oncol. 2021 162 1 226 234 10.1016/j.ygyno.2021.04.029 33934848
    [Google Scholar]
  7. International agency for Rresearch on cancer, world health organization. Female genital tumours: WHO classification of tumours. 5th ed. Lyon: IARC; 2020. Available at: https://www.iarc.who.int/news-events/publication-of-the-who-classification-of-tumours-5th-edition-volume-4-female-genital-tumours/
    [Google Scholar]
  8. Black J.D. English D.P. Roque D.M. Santin A.D. Targeted therapy in uterine serous carcinoma: An aggressive variant of endometrial cancer. Womens Health 2014 10 1 45 57 10.2217/WHE.13.72 24328598
    [Google Scholar]
  9. Soslow RA Tornos C Park KJ Malpica A Matias-Guiu X Oliva E Endometrial carcinoma diagnosis: Use of figo grading and genomic subcategories in clinical practice: Recommendations of the international society of gynecological pathologists. Int. J. Gynecol. Pathol. 2019 Suppl 1 Iss 1 Suppl 1 S64 S74 10.1097/PGP.0000000000000518
    [Google Scholar]
  10. Lee E.K. Liu J.F. Uterine serous carcinoma and uterine carcinosarcoma: Molecular features, clinical advances, and emerging therapies. Clin. Adv. Hematol. Oncol. 2024 22 6 301 310 39110653
    [Google Scholar]
  11. You X. Dong Y. Wang J. Cheng Y. Jia Y. Zhang X. Wang J. The comparison of pure uterine serous carcinoma and mixed tumor with serous component: A single-institution review of 91 cases. BMC Cancer 2024 24 1 99 10.1186/s12885‑023‑11793‑3 38233757
    [Google Scholar]
  12. Black C. Feng A. Bittinger S. Quinn M. Neesham D. McNally O. Uterine papillary serous carcinoma. Int. J. Gynecol. Cancer 2016 26 1 133 140 10.1097/IGC.0000000000000569 26588230
    [Google Scholar]
  13. Zhong X. Wang J. Kaku T. Wang Z. Li X. Wei L. Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study Original Study. Int. J. Gynecol. Cancer 2018 28 6 1138 1144 10.1097/IGC.0000000000001272 29621127
    [Google Scholar]
  14. Crosbie E.J. Kitson S.J. McAlpine J.N. Mukhopadhyay A. Powell M.E. Singh N. Endometrial cancer. Lancet 2022 399 10333 1412 1428 10.1016/S0140‑6736(22)00323‑3 35397864
    [Google Scholar]
  15. Jonge D.M.M. Mooyaart A.L. Vreeswijk M.P.G. Kroon D.C.D. Wezel V.T. Asperen V.C.J. Smit V.T.H.B.M. Dekkers O.M. Bosse T. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. Eur. J. Cancer 2017 72 215 225 10.1016/j.ejca.2016.11.028 28049106
    [Google Scholar]
  16. Cochrane E. Menzies A. Sweeney K. Burke W. Synchronous renal and para-aortic metastasis in a uterine serous carcinoma: A case review and clinical considerations. Gynecol. Oncol. Rep. 2019 28 12 14 10.1016/j.gore.2019.01.009 30740508
    [Google Scholar]
  17. Larish A. Mariani A. Langstraat C. Controversies in the management of early-stage serous endometrial cancer. In Vivo 2021 35 2 671 680 10.21873/invivo.12307 33622859
    [Google Scholar]
  18. Ono K. Hayashi H. Tateno M. Tanaka R. Suzuki R. Maruyama Y. Miyagi Y. Furuya M. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: Clinicopathological analysis of 6 patients. Int. J. Clin. Exp. Pathol. 2014 7 11 7979 7988 25550841
    [Google Scholar]
  19. Wheeler D.T. Bell K.A. Kurman R.J. Sherman M.E. Minimal uterine serous carcinoma: Diagnosis and clinicopathologic correlation. Am. J. Surg. Pathol. 2000 24 6 797 806 10.1097/00000478‑200006000‑00004 10843281
    [Google Scholar]
  20. Hui P. Kelly M. O’Malley D.M. Tavassoli F. Schwartz P.E. Minimal uterine serous carcinoma: A clinicopathological study of 40 cases. Mod. Pathol. 2005 18 1 75 82 10.1038/modpathol.3800271 15389257
    [Google Scholar]
  21. Hui P. Endometrial polyp in postmenopausal women: An epicenter for the development of endometrial serous carcinoma. Arch. Pathol. Lab. Med. 2023 147 4 413 417 10.5858/arpa.2021‑0557‑RA 35512230
    [Google Scholar]
  22. Assem H. Rottmann D. Finkelstein A. Wang M. Ratner E. Santin A.D. Buza N. Hui P. Minimal uterine serous carcinoma and endometrial polyp: A close clinicopathological relationship. Hum. Pathol. 2021 118 1 8 10.1016/j.humpath.2021.09.001 34508766
    [Google Scholar]
  23. Tate K. Yoshida H. Ishikawa M. Uehara T. Ikeda S. Hiraoka N. Kato T. Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. J. Gynecol. Oncol. 2018 29 3 e34 10.3802/jgo.2018.29.e34 29533019
    [Google Scholar]
  24. Zhang F Deng LS Li B Huang MN Li XG Zhang R [Diagnosis, treatment and prognosis of uterine serous carcinoma]. Zhonghua Fu. Chan. Ke. Za. Zhi. 2020 55 12 848 856 10.3760/cma.j.cn112141‑20200716‑00580
    [Google Scholar]
  25. Lin D.I. Fine A. Danziger N.A. Huang R.S.P. Mata D.A. Decker B. Killian J.K. Ramkissoon S.H. Lechpammer M. Janovitz T. Ross J.S. Sokol E.S. Elvin J.A. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. Gynecol. Oncol. 2022 164 3 558 565 10.1016/j.ygyno.2021.12.030 34998597
    [Google Scholar]
  26. Abu-Rustum N.R. Yashar C.M. Bradley K. Campos S.M. Chino J. Chon H.S. Chu C. Cohn D. Crispens M.A. Damast S. Diver E. Fisher C.M. Frederick P. Gaffney D.K. George S. Giuntoli R. Han E. Howitt B. Huh W.K. Lea J. Mariani A. Mutch D. Nekhlyudov L. Podoll M. Remmenga S.W. Reynolds R.K. Salani R. Sisodia R. Soliman P. Tanner E. Ueda S. Urban R. Wethington S.L. Wyse E. Zanotti K. McMillian N.R. Motter A.D. NCCN guidelines® insights: Uterine neoplasms, version 3.2021. J. Natl. Compr. Canc. Netw. 2021 19 8 888 895 10.6004/jnccn.2021.0038 34416706
    [Google Scholar]
  27. Bogani G. Ditto A. Maggiore L.R.U. Scaffa C. Mosca L. Chiappa V. Martinelli F. Lorusso D. Raspagliesi F. Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. Tumori 2019 105 1 92 97 10.1177/0300891618784785 29984612
    [Google Scholar]
  28. Concin N. Matias-Guiu X. Vergote I. Cibula D. Mirza M.R. Marnitz S. Ledermann J. Bosse T. Chargari C. Fagotti A. Fotopoulou C. Martin G.A. Lax S. Lorusso D. Marth C. Morice P. Nout R.A. O’Donnell D. Querleu D. Raspollini M.R. Sehouli J. Sturdza A. Taylor A. Westermann A. Wimberger P. Colombo N. Planchamp F. Creutzberg C.L. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 2021 31 1 12 39 10.1136/ijgc‑2020‑002230 33397713
    [Google Scholar]
  29. Koh W.J. Abu-Rustum N.R. Bean S. Bradley K. Campos S.M. Cho K.R. Chon H.S. Chu C. Cohn D. Crispens M.A. Damast S. Dorigo O. Eifel P.J. Fisher C.M. Frederick P. Gaffney D.K. George S. Han E. Higgins S. Huh W.K. Lurain J.R. III Mariani A. Mutch D. Nagel C. Nekhlyudov L. Fader A.N. Remmenga S.W. Reynolds R.K. Tillmanns T. Ueda S. Wyse E. Yashar C.M. McMillian N.R. Scavone J.L. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2018 16 2 170 199 10.6004/jnccn.2018.0006 29439178
    [Google Scholar]
  30. Unsal M. Kilic C. Cakir C. Kilic F. Ersak B. Karakas S. Tokgozoglu N. Varli B. Oktar O. Comert K.G. Ozdemir I.A. Boran N. Toptas T. Ureyen I. Korkmaz V. Taskin S. Tekin MO. Ustun Y. Tasci T. Ortac F. Turan T. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: A Turkish multicentric study. J. Obstet. Gynaecol. 2023 43 1 2151355 10.1080/01443615.2022.2151355 36503383
    [Google Scholar]
  31. Sanchez N.J.M. Finkelman B.S. Turner B.M. Katerji H. Wang X. Varghese S. Wang T. Peng Y. Hicks D.G. Zhang H. HER2 in uterine serous carcinoma: Current state and clinical perspectives. Am. J. Clin. Pathol. 2023 160 4 341 351 10.1093/ajcp/aqad056 37267036
    [Google Scholar]
  32. Banet N. Shahi M. Batista D. Yonescu R. Tanner E.J. Fader A.N. Cimino-Mathews A. HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma. Am. J. Surg. Pathol. 2021 45 5 708 715 10.1097/PAS.0000000000001682 33739786
    [Google Scholar]
  33. Menderes G. Lopez S. Han C. Altwerger G. Gysler S. Varughese J. Schwartz P.E. Santin A.D. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. Discov. Med. 2018 26 141 39 50 30265854
    [Google Scholar]
  34. Gray C Argáez C. Trastuzumab combination and monotherapy for her2 advanced or recurrent uterine or endometrial cancer: A review of clinical effectiveness and cost-effectiveness. 2020 Available from: https://pubmed.ncbi.nlm.nih.gov/33534446/
  35. Lee E.K. Fader A.N. Santin A.D. Liu J.F. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecol. Oncol. 2021 160 1 322 332 10.1016/j.ygyno.2020.10.017 33160694
    [Google Scholar]
/content/journals/cas/10.2174/0118746098347939250407050519
Loading
Subtle Intrusion: Minimal Serous Uterine Carcinoma in an Asymptomatic Postmenopausal Patient-A Case Report
Bentham Science Publishers ; https://doi.org/10.2174/0118746098347939250407050519
/content/journals/cas/10.2174/0118746098347939250407050519
/content/journals/cas/10.2174/0118746098347939250407050519
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: histopathology ; postmenopausal woman ; endometrial cancer ; pelvic lymph nodes ; Endometrial polyp ; estrogen receptor ; uterine serous carcinoma ; minimal uterine serous carcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test